FFAR2 expressing myeloid-derived suppressor cells drive cancer immunoevasion

Zeda Zhao,Juliang Qin,Ying Qian,Chenshen Huang,Xiaohong Liu,Ning Wang,Liqin Li,Yuqing Chao,Binghe Tan,Na Zhang,Min Qian,Dali Li,Mingyao Liu,Bing Du
DOI: https://doi.org/10.1186/s13045-024-01529-6
IF: 28.5
2024-02-26
Journal of Hematology & Oncology
Abstract:Emerging evidences suggest that aberrant metabolites contributes to the immunosuppressive microenvironment that leads to cancer immune evasion. Among tumor immunosuppressive cells, myeloid-derived suppressor cells (MDSCs) are pathologically activated and extremely immunosuppressive, which are closely associated with poor clinical outcomes of cancer patients. However, the correlation between MDSCs mediated immunosuppression and particular cancer metabolism remained elusive.
oncology,hematology
What problem does this paper attempt to address?
This paper mainly discusses the accumulation of short-chain fatty acids (SCFAs), particularly acetate, in the tumor microenvironment and its impact on cancer immune evasion. The study found that acetate accumulates significantly in human lung cancer tissues, spontaneous lung cancer in mice, and subcutaneous tumor models, promoting immune suppression and cancer progression through the activation of free fatty acid receptor 2 (FFAR2). Specifically, FFAR2 is highly expressed in myeloid-derived suppressor cells (MDSCs) from lung cancer patients' tumors, which is closely associated with poor prognosis. The study also showed that complete or selective deletion of the Ffar2 gene in myeloid cells significantly inhibited uracil-induced lung carcinogenesis and allograft tumor growth, manifested by reduced MDSCs and increased CD8+ T cell infiltration. Mechanistically, the loss of FFAR2 in MDSCs significantly reduced the expression of arginase 1 (Arg1) via the Gαq/calcium/PPAR-γ axis, thus eliminating T cell dysfunction caused by L-arginine consumption in the tumor microenvironment. Therefore, supplementing L-arginine or inhibiting PPAR-γ can significantly restore acetate/FFAR2-mediated T cell suppression. Finally, the inhibition of FFAR2 overcomes resistance to immune checkpoint blockade by enhancing the recruitment of tumor-infiltrating T cells and cytotoxicity. In summary, the results of this study demonstrate that the acetate/FFAR2 axis enhances MDSC-mediated immune suppression through the Gαq/calcium/PPAR-γ/Arg1 signaling pathway, thereby promoting cancer progression. Therefore, FFAR2 may serve as a novel target for eliminating pathologically activated MDSCs and reversing immune-suppressive tumor microenvironment, with great potential to improve the clinical outcomes of cancer immunotherapy.